1. Jim Harrison Jim Harrison United States says:

    Pfizer and Merck are late to the game.  Oramed Pharmaceuticals (NASDAQ:ORMP). Has been working on an Oral pill for some time. The first trial involved 24 unvaccinated volunteers, each taking one or two pills, before moving on to larger Phase 3 trials. The vaccine should be "much more resistant to COVID-19 variants," according to Oramed CEO Nadav Kidron, since it trains the immune system against three viral proteins instead of the single protein targeted by Pfizer and Moderna's (NASDAQ:MRNA) shots.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment